Investigational Drug Pharmacist

Rotations Precepted

Investigational Drug Service

Pharmacy School/Graduation Year

Drake University College of Pharmacy and Health Sciences, 2004

Residency Training Program Location/Year

  • PGY-1 Pharmacy Practice Residency, Clement J. Zablocki VA Medical Center, Milwaukee, WI, 2004-2005
  • PGY-2 Infectious Diseases Pharmacy Residency, Oklahoma City VA Medical Center, 2005-2006
  • Clinical Antiretroviral Research Fellowship, National Institutes of Health, Bethesda, MD 2006-2008

Professional Interests

Institutional Review Board (IRB), Pharmacy Research Committee, Early Phase Research

Projects

  • Assessment of Compliance with Outpatient Beacon Treatment Plan Update Requests for Patients Currently Receiving Investigational Therapies (7/15-7/16)
  • Medication History and Concomitant Medication Review in Early-Phase Investigational Oral Anticancer Clinical Trials: Pharmacist Consult Service Pilot (7/14-7/15)

Awards and Certifications

  • BCPS (Board Certified Pharmacotherapy Specialist)
  • 2010 ASHP Foundation Drug Therapy Research Award

Publications

  • Busse KH, Hadigan C, Chairez C, et al. Gemfibrozil Concentrations are Significantly Decreased in the Presence of Lopinavir/ritonavir. J Acquir Immune Defic Syndr 2009; 52: 235–239.
  • Gentry CA, Gross KB, Sud B, Drevets D. Adverse outcomes associated with the use of drotrecogin alfa (activated) in septic patients with baseline bleeding precautions. Crit Care Med. 2009; 37: 19-25.
  • Ramanathan R, Pau AK, Busse KH, et al. Iatrogenic Cushing Syndrome after Epidural Triamcinolone Injections in an HIV Type 1-Infected Patient Receiving Therapy with Ritonavir-Lopinavir. Clin Infect Dis. 2008;47: e97-9.
  • Busse K, Formentini E, Alfaro RM, Kovacs J, Penzak SR. Influence of antiretrovirals on prednisolone pharmacokinetics in HIV-positive individuals. J Acquir Immune Defic Syndr. 2008; 48: 561-6.
  • Penzak SR, Busse K, Robertson SM, Formentini E, Alfaro RM, Davy R. Limitations of using a Single Post-Dose Midazolam Concentration to predict CYP3A-Mediated Drug Interactions. J Clin Pharmacol. 2008; 48: 671-80.
  • Busse K, Penzak SR. Darunavir: A second generation protease inhibitor. Am J Health-Syst Pharm. 2007;64:1593-1602.

Hobbies

Fat biking, hiking, reading, playing with my kids

Favorite Things to Do in Milwaukee

Going to festivals in the summer, finding new craft brews, eating at new restaurants